Better Therapeutics has become the latest company in the digital health sector to announce big job cuts, saying it needs to conserve cash as it waits for FDA approval of i
Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January.
Just days after Eli Lilly announced plans to cut the price of its insulin products in the US, Novo Nordisk has followed suit with reductions of up to 75% from the start of
Sanofi has agreed a deal to buy US biopharma company Provention Bio for $2.9 billion, taking control of a recently-approved type 1 diabetes (T1D) prevention therapy Tzield
Sanofi has formed another partnership to support its vision of insulin-based therapies that are connected with glucose monitoring devices and make it easier for patients t
Eli Lilly is leaving nothing to chance when it comes to making the most of its fast-growing diabetes therapy Mounjaro – it is investing another $450million at a facility in North Carolina t
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough